C4 Therapeutics Appoints Utpal Koppikar to Board of Directors
March 16, 2022 16:05 ET
|
C4 Therapeutics, Inc.
– Utpal Koppikar, Veteran Life Sciences Industry Financial Executive, Appointed as Independent Member of the Board of Directors, Chair of Audit Committee and Member of Organization, Leadership and...
C4 Therapeutics Announces FDA Orphan Drug Designation for CFT8634 for the Treatment of Soft Tissue Sarcoma
March 09, 2022 08:00 ET
|
C4 Therapeutics, Inc.
WATERTOWN, Mass., March 09, 2022 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation...
C4 Therapeutics to Present at the American Association for Cancer Research (AACR) Annual Meeting 2022
March 08, 2022 16:30 ET
|
C4 Therapeutics, Inc.
- Clinical Data from Cohort A of the Ongoing Phase 1/2 Trial of CFT7455, a Novel IKZF1/3 Degrader, Accepted as Late-Breaker Poster Presentation – - New Pre-clinical Data from CFT7455; CFT8634, a...
C4 Therapeutics Reports Full Year 2021 Financial Results and Recent Business Highlights
February 24, 2022 07:00 ET
|
C4 Therapeutics, Inc.
– Data from Cohort A of the Ongoing Phase 1/2 Trial of CFT7455, a Novel IKZF1/3 Degrader, Accepted for Presentation at the American Association for Cancer Research (AACR) Annual Meeting – –...
C4 Therapeutics Announces 2022 Key Milestones to Advance Targeted Protein Degradation Portfolio
January 10, 2022 07:00 ET
|
C4 Therapeutics, Inc.
– Initial Phase 1 Data for CFT7455, a Novel IKZF1/3 Degrader, Expected in 1H 2022– – IND Clearance Achieved for CFT8634, a Degrader Targeting BRD9; On Track to Initiate Phase 1 Trial in Synovial...
C4 Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 03, 2022 07:00 ET
|
C4 Therapeutics, Inc.
WATERTOWN, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that...
C4 Therapeutics Added to NASDAQ Biotechnology Index
December 17, 2021 08:00 ET
|
C4 Therapeutics, Inc.
WATERTOWN, Mass., Dec. 17, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that...
C4 Therapeutics Reports Recent Business Highlights and Third Quarter 2021 Financial Results
November 10, 2021 16:01 ET
|
C4 Therapeutics, Inc.
– Phase 1/2 study of CFT7455, a Novel IKZF1/3 Degrader, Progressing with Data Expected in 2022; Trial-in-Progress Poster Accepted for Presentation at 63rd ASH Annual Meeting – – Investigational New...
C4 Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results
August 11, 2021 16:02 ET
|
C4 Therapeutics, Inc.
– Dosed First Patient in Phase 1/2 Clinical Trial of CFT7455, a novel IKZF1/3 Degrader, in Hematologic Malignancies; Data Expected in 2022 – – Received Orphan Drug Designation for CFT7455 for the...
C4 Therapeutics Announces FDA Orphan Drug Designation for CFT7455 for the Treatment of Multiple Myeloma
August 11, 2021 16:01 ET
|
C4 Therapeutics, Inc.
WATERTOWN, Mass., Aug. 11, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that...